Oncology

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

Oncology

ASCO 2023 – Corina Dutcus

At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major

News

Seagen says Adcetris/Opdivo combo aces lymphoma trial

Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for t

Oncology

Science demands more patient centricity in oncology research

It’s simple: a clinical trial health system that enrols more patients will lead to faster treatment advances and, therefore, better outcomes for people with cancer.1 But, as it s

Oncology

ASCO 2023 – Gregory Lubiniecki

With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.

News

ASCO: AI-powered MOSAIC will build 3D atlas for cancer

In amongst the big clinical trial readouts at ASCO, a new research project made its official debut with the ambitious goal of mapping cancer cells’ interactions with their

Kura files $100m offer after menin inhibitor results in AML...

ASCO 2023 – Corina Dutcus

Seagen says Adcetris/Opdivo combo aces lymphoma trial

Science demands more patient centricity in oncology research

ASCO 2023 – Gregory Lubiniecki

ASCO: AI-powered MOSAIC will build 3D atlas for cancer

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks